Raghav

Canceronclive.com

Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses adjusting dosing with regorafenib (Stivarga) in patients with colorectal cancer (CRC).
Canceronclive.com

Dr. Raghav on Selecting Treatment with TAS-102 vs Regorafenib in CRC

Kanwal Raghav, MBBS, MD, discusses the process for selecting between treatment with trifluridine and tipiracil vs regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the process for selecting between treatment with trifluridine and tipiracil (Lonsurf; TAS-102) vs regorafenib (Stivarga) in patients with colorectal cancer (CRC).
RELATED CHANNELS
Canceronclive.com

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the utility of chemotherapy-free intervals in colorectal cancer (CRC).
Canceronclive.com

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer (CRC).
Canceronclive.com

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer. Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer (mCRC).